Objective: We present the 1st case of prepubertal hyperandrogenism because of a defect in the conversion of cortisone (E) to cortisol (F) by hepatic11β-hydroxysteroid dehydrogenase type 1. Methods and Results: Clinical and anthropometric data were obtained. Serum androgens and gonadotropins with luteinizing hormone releasing hormone stimulation test, dexamethasone suppression test, and corticotropin-releasing hormone stimulation test were evaluated. Adrenal imaging and urinary steroid profiling by gas chromatography/mass spectrometry were employed. A 6.9-year-old boy presented with precocious pubarche, height (+2.6 SD), accelerated bone age (11.5 years), and Tanner stage 2 pubic hair and genitalia. Serum androgen levels were elevated and dexamethasone suppressible. Serum F was normal, but the E concentration was increased. Central precocious puberty and congenital adrenal hyperplasia were excluded. The excretion of androgen metabolites was moderately increased, but a highly increased tetrahydrocortisone (THE) and a diminished tetrahydrocortisol (THF + allo-THF) excretion was found with a [THF + allo-THF/ THE] ratio of 0.032 (normal controls 1.05 ± 0.17). The corticotropin-releasing hormone stimulation test showed an exaggerated adrenocorticotropic hormone response, suggesting a relative deficiency of F. Two months of hydrocortisone treatment (17.5 mg daily) failed to suppress androgens adequately. Treatment with dexamethasone (0.375 mg/daily) resulted in androgen suppression. Conclusions: In the case of precocious pubarche and accelerated growth, the diagnosis of 11β-hydroxysteroid dehydrogenase type 1 deficiency (‘apparent cortisone reductase deficiency’) should be considered. The diagnosis is based on determinations of urinary steroid metabolites.

Keywords:
11β-Hydroxysteroid dehydrogenase type 1, Apparent cortisone reductase deficiency, Adrenal hyperandrogenism, Urinary steroid profile
1.
Tomlinson JW, Stewart PM: Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase. Best Pract Res Clin Endocrinol Metab 2001;15:61–78.
2.
Quinkler M, Oelkers W, Diedrich: Clinical implications of glucocorticoid metabolism by 11β-hydroxysteroid dehydrogenases in target tissues. Eur J Endocrinol 2001;144:87–97.
3.
Taylor N, Bartlett WA, Dawson DJ: Cortisone reductase deficiency: Evidence for a new inborn error in metabolism of adrenal steroids. J Endocrinol 1984;102(suppl):89.
4.
Phillopou G, Higgins BA: A new defect in the peripheral conversion of cortisone to cortisol. J Steroid Biochem 1985;22:435–436.
5.
Taylor NF, Pollock A, Dornan TL: Corticosteroid 11-reductase deficiency: Steroid studies in a further family. J Clin Invest 1990;13(suppl 2):238.
6.
Savage MW, Barton RN, Dornan TL, Horan MA, Robins AJ, Taylor NF: Increased metabolic clearance of cortisol in corticosteroid 11-reductase deficiency. J Endocrinol 1991;129(suppl):219.
7.
Phillipov G, Palermo M, Shackleton CH: Apparent cortisone reductase deficiency: A unique form of hypercortisolism. J Clin Endocrinol Metab 1996;81:3885–3860.
8.
Jamiesson A, Wallace AM, Andrew R, Nunez BS, Walker BR, Fraser R, White PC, Connell JM: Apparent cortisone reductase deficiency: A functional defect in 11beta-hydroxysteroid dehydrogenase type I. J Clin Endocrinol Metab 1999;84:3570–3574.
9.
Biason-Lauber A, Suter SL, Shackleton CH, Zachmann M: Apparent cortisone reductase deficiency: A rare cause of hyperandrogenemia and hypercortisolism. Horm Res 1999;53:260–266.
10.
Filipek M, Wawer ZT, Ruszczyńska-Wolska A, Podleśny J: HPLC method for the determination of cortisone, hydrocortisone, 21-deoxycortisol and 11-deoxycortisol in human plasma, and its use in diagnosis of congenital adrenal hyperplasia (abstract). Ann Diagn Paediatr Pathol 1997;1:201.
11.
Shackleton CHL: Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research. J Steroid Biochem Mol Biol 1993;45:127–140.
12.
Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamiesson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ: 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997;94:14924–14292.
13.
Taniyama M, Honma K, Ban Y: Urinary cortisol metabolites in the assessment of peripheral thyroid hormone action: Application for diagnosis of resistance to thyroid hormone. Thyroid 1993;3:229–233.
14.
Diederich S, Grossmann C, Hanke B, Quinkler M, Herrmann M, Bähr V, Oelkers W: In the search for specific inhibitors of human 11β-hydroxysteroid dehydrogenases (11β-HSDs): Chenodeoxycholic acid selectively inhibits 11β-HSD-I. Eur J Endocrinol 2000;142:200–207.
15.
Diederich S, Hanke B, Oelkers W, Bähr V: Metabolism of dexamethasone in the human kidney: Nicotinamide adenine dinucleotide-dependent 11β-reduction. J Clin Endocrinol Metab 1997;82:1598–1602.
16.
Maser E, Oppermann UC: The 11β-hydroxysteroid dehydrogenase system, a determinant of glucocorticoid and mineralocorticoid action: Role of type-1 11β-hydroxysteroid dehydrogenase in detoxification process. Eur J Biochem 1997;249:365–369.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.